Go to content Go to menu Go to search

ImmunID: successful validation of IFS4 immune forecast station on a Roche Diagnostics France quantitative 480 PCR system

21 April 2011

  • version française

ImmunID Technologies aims at becoming a leading provider of solutions for the characterization and analysis of the immune system repertoire and the tracking of immune malfunctions. The company has established a technical collaboration for quantitative PCR with Roche Diagnostics France as part of its program for the industrialization and standardization of its 4th generation IFS stations.

The aim of this collaboration was to qualify an IFS4 used in the Infectiology Center in Lyon by members of the PLATINE consortium. The project was successful in under 12 months thanks to the effective collaboration between the Applied Science department at Roche Diagnostics France and ImmunID.

"The results of this first technical collaboration between two members of
Lyonbiopôle are very encouraging. They demonstrate that the LightCycler 480 is a flexible research instrument whose reliability makes a standardized technical approach possible for multiple parallel PCR reactions. This collaboration also validated a complete workflow integrating the LightCycler 480 and allowing the molecular biology analyses developed by ImmunID to reach a higher level of automation. This type of standardization is essential for the future implementation of ImmunID's tests on our quantitative PCR machines for routine diagnosis in specialized biology laboratories", indicates Frank Willemse, marketing director at Roche Diagnostics France.

Improving assessment of the benefit/risk ratio for treatments

"We are delighted with the results of this collaboration between the French leader of in vitro diagnosis, Roche Diagnostics France, and a startup like ImmunID. They will help accelerate the time to market for innovative tests measuring the immune repertoire. By ranking patients according to their immune repertoire, these tests will help improve the success rate for clinical
studies run by the pharmaceutical industry. Tests can be used from the phase of patient enrolment in the study, and throughout clinical follow-up. They will help improve assessment of the benefit/risk ratio for treatments, and will be instrumental in developing personalized medicine", indicates Nicolas Pasqual, president of ImmunID.

"The qualification of the IFS4 platform is the fruit of an active collaboration between Roche Diagnostics France and ImmunID at Lyonbiopôle's Infectiology Center. This success allows us to confidently offer immune repertoire analysis for patients enrolled in the clinical trials in which our company participates" adds Jean-François Mouret, CTO at ImmunID.

"The favourable results recently obtained by ImmunID Technologies as part of their technical collaboration with Roche Diagnostics France once again illustrate how the world-class competitiveness cluster, Lyonbiopole, contributes to catalyzing innovation. We are very pleased to contribute to scientific animation and partnerships between multinationals and SMBs. This provided ImmunID with access to the infectious diseases center at Lyonbiopôle as part of the "PLATINE" collaboration, and allowed qualification of their immune forecast station on a Roche Diagnostics system. Lyonbiopôle thus confirms its role in driving innovation and stimulating evolution in the fields of diagnosis, vaccines and biotherapies" concludes Yves Laurent, general manager at Lyonbiopole.

Find out more

Located in Grenoble and Lyon, ImmunID is leader in the field of analysis of immune repertoire combinatorial diversity. Thanks to the original concept of "immune forecast", ImmunID offers diagnostic and innovative immunomonitoring solutions to characterize immune system dysfunctions, or to analyze the impact of immunotherapies on the immune repertoire.

In the Biotech & Pharma sector, the ImmunTraCkeR® and Immun’Ig® solutions are used from the discovery stage through to clinical validation to measure the safety and efficacy of active molecules, including monoclonal antibodies (e.g. anti-CD20), interleukins (IL-2, IL-7 etc.), and vaccines (prophylactic and therapeutic).